HomeCompareAYX vs ABBV

AYX vs ABBV: Dividend Comparison 2026

AYX yields 4.14% · ABBV yields 3.06%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 ABBV wins by $76.1K in total portfolio value
10 years
AYX
AYX
● Live price
4.14%
Share price
$48.26
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$26.2K
Annual income
$540.67
Full AYX calculator →
ABBV
AbbVie Inc.
● Live price
3.06%
Share price
$217.44
Annual div
$6.65
5Y div CAGR
40.6%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$102.3K
Annual income
$24,771.77
Full ABBV calculator →

Portfolio growth — AYX vs ABBV

📍 ABBV pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodAYXABBV
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, AYX + ABBV cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
AYX pays
ABBV pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

AYX
Annual income on $10K today (after 15% tax)
$352.26/yr
After 10yr DRIP, annual income (after tax)
$459.57/yr
ABBV
Annual income on $10K today (after 15% tax)
$259.96/yr
After 10yr DRIP, annual income (after tax)
$21,056.00/yr
At 15% tax rate, ABBV beats the other by $20,596.43/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of AYX + ABBV for your $10,000?

AYX: 50%ABBV: 50%
100% ABBV50/50100% AYX
Portfolio after 10yr
$64.3K
Annual income
$12,656.21/yr
Blended yield
19.69%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on ABBV right now

AYX
Analyst Ratings
14
Buy
11
Hold
Consensus: Buy
Price Target
$80.86
+67.6% upside vs current
Range: $50.00 — $125.00
Altman Z
1.2
Piotroski
4/9
ABBV
Analyst Ratings
27
Buy
12
Hold
1
Sell
Consensus: Buy
Price Target
$256.15
+17.8% upside vs current
Range: $223.00 — $299.00
Altman Z
2.0
Piotroski
8/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

AYX buys
0
ABBV buys
0
No recent congressional trades found for AYX or ABBV in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricAYXABBV
Forward yield4.14%3.06%
Annual dividend / share$2.00$6.65
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%40.6%
Portfolio after 10y$26.2K$102.3K
Annual income after 10y$540.67$24,771.77
Total dividends collected$4.8K$61.0K
Payment frequencyquarterlyquarterly
SectorStockHealthcare
Analyst consensusBuyBuy
Analyst price target$80.86$256.15

Year-by-year: AYX vs ABBV ($10,000, DRIP)

YearAYX PortfolioAYX Income/yrABBV PortfolioABBV Income/yrGap
1← crossover$11,114$414.42$11,550$430.00$436.00ABBV
2$12,323$430.47$13,472$627.96$1.1KABBV
3$13,632$446.05$15,906$926.08$2.3KABBV
4$15,047$461.14$19,071$1,382.55$4.0KABBV
5$16,576$475.72$23,302$2,095.81$6.7KABBV
6$18,226$489.78$29,150$3,237.93$10.9KABBV
7$20,005$503.31$37,536$5,121.41$17.5KABBV
8$21,922$516.30$50,079$8,338.38$28.2KABBV
9$23,985$528.75$69,753$14,065.80$45.8KABBV
10$26,205$540.67$102,337$24,771.77$76.1KABBV

AYX vs ABBV: Complete Analysis 2026

AYXStock

Alteryx, Inc. operates in analytic process automation business in the Asia-Pacific, Europe, the Middle East, Africa, Latin America, and internationally. The company's analytics platform enables organizations to enhance business outcomes and the productivity of their business analysts, data scientists, citizen data scientists, and data engineers. Its analytics platform comprises Alteryx Designer, a data profiling, preparation, blending, analytics, data science, and process automation product; Alteryx Server, a server-based product to manage, automate, and govern processes and applications in a web-based environment; Alteryx Intelligence Suite, an augmented machine learning, auto-modeling, and text mining product; Alteryx Connect, a collaborative data exploration platform; and Alteryx Promote, an analytics model management product for data scientists and analytics teams to build, manage, monitor, and deploy predictive models into real-time production applications. The company's platform also offers cloud-native products comprising Alteryx Designer Cloud, a browser-based version of Alteryx Designer product; Alteryx Machine Learning, an automated machine learning product to build, validate, iterate, and explore machine learning models; Alteryx Auto Insights, an analytics solution that automates insights for business users; and Alteryx Trifacta, an open and interactive cloud platform for data engineers and analysts to collaboratively profile, prepare, and pipeline data for analytics and machine learning. In addition, it provides technical support, instruction, and customer services. It serves retail, food services, consumer products, telecom and cable, media and entertainment, professional services, financial services, energy and utilities, public sector, manufacturing, travel and hospitality, healthcare and insurance, and technology industries. The company was founded in 1997 and is headquartered in Irvine, California.

Full AYX Calculator →

ABBVHealthcare

AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production, as well as other eye care products. AbbVie Inc. has a research collaboration with Dragonfly Therapeutics, Inc. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.

Full ABBV Calculator →
📬

Get this AYX vs ABBV comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

AYX vs SCHDAYX vs JEPIAYX vs OAYX vs KOAYX vs MAINAYX vs JNJAYX vs MRKAYX vs PFE

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.